Table 2.
Alternative transcripts as percentages of total tyrosinase transcripts in amelanotic primary (P) melanomas and their amelanotic metastases (M)
| Sample | Principal alternative mRNAs* | Δ3/Δ4/Δ1e | Δ1b | Δ1d |
|---|---|---|---|---|
| WT skin | 15.5 | 11.7 | 0.6 | 0.8 |
| 488P | 26.9 | 16.9 | 3.2 | 2.7 |
| M-liver | — | — | — | — |
| 490P1 | — | — | — | — |
| P2 | 20.8 | 13.7 | 2.2 | 1.4 |
| M-LN | — | — | — | — |
| M-Lung | 14.6 | 9.2 | 1.4 | 2.1 |
| 492P | — | — | — | — |
| M-Liver | — | — | — | — |
| 502P | 18.7 | 13.3 | 2.1 | 1.2 |
| M-Lung | 20.2 | 9.3 | 6.3 | 2.3 |
| 607P | 21.5 | 12.1 | 3.5 | 2.3 |
| M-LN | 13.9 | 10.1 | 0.8 | 0.9 |
| M-Lung | 15.0 | 11.7 | 0.6 | 0.7 |
WT, wild type; LN, lymph node.
*
In this group are most of the relatively abundant alternative transcripts detected by the prTyr probe, including the Δ3/Δ4/Δ1e comigrating transcripts, Δ1b, and Δ1d, and excluding transcripts of low abundance (<0.1 molecule per ng of RNA). —, Lack of detectable transcripts.